US8715645B2
(en)
*
|
1994-05-27 |
2014-05-06 |
The Regents Of The University Of Colorado |
Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
|
US6046048A
(en)
*
|
1996-01-09 |
2000-04-04 |
Genetech, Inc. |
Apo-2 ligand
|
US6998116B1
(en)
*
|
1996-01-09 |
2006-02-14 |
Genentech, Inc. |
Apo-2 ligand
|
US6030945A
(en)
*
|
1996-01-09 |
2000-02-29 |
Genentech, Inc. |
Apo-2 ligand
|
US20050089958A1
(en)
*
|
1996-01-09 |
2005-04-28 |
Genentech, Inc. |
Apo-2 ligand
|
US20040047864A1
(en)
*
|
1996-03-14 |
2004-03-11 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule I
|
WO1997046686A2
(fr)
*
|
1996-06-07 |
1997-12-11 |
Amgen Inc. |
Polypeptide apparente au facteur de necrose tumorale
|
EP0951551B9
(fr)
|
1996-12-23 |
2012-12-26 |
Immunex Corporation |
Ligand pour l'activateur des recepteurs du nf-kappab, ligand membre de la superfamille de tnf
|
US8329179B2
(en)
*
|
1997-01-28 |
2012-12-11 |
Human Genome Sciences, Inc. |
Death domain containing receptor 4 antibodies and methods
|
US7452538B2
(en)
|
1997-01-28 |
2008-11-18 |
Human Genome Sciences, Inc. |
Death domain containing receptor 4 antibodies and methods
|
ES2284199T5
(es)
*
|
1997-01-28 |
2011-11-14 |
Human Genome Sciences, Inc. |
Receptor 4 que contiene dominio de muerte (dr4: receptor 4 de muerte), miembro de la superfamilia de receptores de tnf y unión a trail (apo-2l).
|
US6433147B1
(en)
|
1997-01-28 |
2002-08-13 |
Human Genome Sciences, Inc. |
Death domain containing receptor-4
|
US20020009467A1
(en)
|
1997-01-29 |
2002-01-24 |
Shozo Koyama |
Antigenic substance inductor, vaccine precursor, vaccine, antibody, neutralizing antibody, antitoxin, idiotype antibody and/or anti-idiotype antibody which is induced by its idiotype antibody
|
JP3813682B2
(ja)
*
|
1997-01-29 |
2006-08-23 |
小山 省三 |
ワクチン前駆体およびワクチン
|
EP0977887A2
(fr)
*
|
1997-02-12 |
2000-02-09 |
Abbott Laboratories |
Element de la famille tnf utilise pour le traitement et le diagnostic d'une maladie
|
US7528239B1
(en)
*
|
1997-02-13 |
2009-05-05 |
Immunex Corporation |
Receptor that binds trail
|
US6072047A
(en)
|
1997-02-13 |
2000-06-06 |
Immunex Corporation |
Receptor that binds trail
|
US20010010924A1
(en)
*
|
1997-03-14 |
2001-08-02 |
Keith Charles Deen |
Tumor necrosis factor related receptor, tr6 polynecleotides
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
US20080248046A1
(en)
*
|
1997-03-17 |
2008-10-09 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US20040136951A1
(en)
*
|
1997-03-17 |
2004-07-15 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
JP4330180B2
(ja)
*
|
1997-03-17 |
2009-09-16 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
死ドメイン含有レセプター5
|
US20050233958A1
(en)
*
|
1997-03-17 |
2005-10-20 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US20020102706A1
(en)
*
|
1997-06-18 |
2002-08-01 |
Genentech, Inc. |
Apo-2DcR
|
US6316408B1
(en)
|
1997-04-16 |
2001-11-13 |
Amgen Inc. |
Methods of use for osetoprotegerin binding protein receptors
|
EA003636B1
(ru)
*
|
1997-04-16 |
2003-08-28 |
Амген Инк. |
Остеопротегеринсвязующие белки и рецепторы
|
US20100152426A1
(en)
*
|
1997-05-15 |
2010-06-17 |
Ashkenazi Avi J |
Apo-2 receptor fusion proteins
|
DE69838249T3
(de)
*
|
1997-05-15 |
2012-01-19 |
Genentech, Inc. |
Anti-apo-2 antikörper
|
US6342369B1
(en)
*
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
CA2293740A1
(fr)
*
|
1997-06-18 |
1998-12-23 |
Genentech, Inc. |
Apo-2dcr, un recepteur relie au tnf
|
US6171787B1
(en)
|
1997-06-26 |
2001-01-09 |
Abbott Laboratories |
Member of the TNF family useful for treatment and diagnosis of disease
|
AU8400398A
(en)
*
|
1997-07-11 |
1999-02-08 |
Trustees Of The University Of Pennsylvania, The |
Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
|
FR2766713B1
(fr)
*
|
1997-08-04 |
1999-09-24 |
Bio Merieux |
Facteur proteique associe a une maladie neuro-degenerative et/ou auto-immune et/ou inflammatoire
|
US6346388B1
(en)
|
1997-08-13 |
2002-02-12 |
Smithkline Beecham Corporation |
Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
|
WO1999050416A1
(fr)
*
|
1997-09-30 |
1999-10-07 |
Pharmacia & Upjohn Company |
Identification de ligand d'apoptose liee au tnf
|
IL135911A0
(en)
*
|
1997-11-18 |
2001-05-20 |
Genentech Inc |
Dna 19355 polypeptide, a tumor necrosis factor homolog
|
US7019119B2
(en)
*
|
1997-12-12 |
2006-03-28 |
The Rockefeller University |
Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
|
JP2002508962A
(ja)
*
|
1998-01-15 |
2002-03-26 |
ジェネンテク・インコーポレイテッド |
Apo−2リガンド
|
US20040120947A1
(en)
*
|
1998-01-26 |
2004-06-24 |
Genentech, Inc. |
DR4 antibodies and uses thereof
|
US20040180049A1
(en)
*
|
1998-01-26 |
2004-09-16 |
Genentech, Inc. |
DR4 antibodies and uses thereof
|
EP2050762A3
(fr)
|
1998-03-10 |
2009-07-08 |
Genentech, Inc. |
Nouvelles polypeptides et acides nucléiques les codant
|
JP2002507404A
(ja)
*
|
1998-03-27 |
2002-03-12 |
ジェネンテク・インコーポレイテッド |
Apo−2リガンド−抗HER−2抗体相乗作用
|
EP1941905A1
(fr)
|
1998-03-27 |
2008-07-09 |
Genentech, Inc. |
Synergie d'anticorps APO-2 ligand-anti-her-2
|
JP2002517223A
(ja)
*
|
1998-06-12 |
2002-06-18 |
ジェネンテック・インコーポレーテッド |
モノクローナル抗体、交叉反応性抗体およびそれを生成する方法
|
EP2311490A3
(fr)
|
1998-07-13 |
2011-05-04 |
Board of Regents, The University of Texas System |
L'utilisation d'anticorps vis-à-vis des aminophospholipides pour le traitement du cancer
|
WO2000026228A1
(fr)
*
|
1998-11-02 |
2000-05-11 |
Clontech Laboratories, Inc. |
Gene et proteine regulant la mort cellulaire
|
US20030187196A1
(en)
*
|
1998-12-30 |
2003-10-02 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20050281821A1
(en)
*
|
1999-01-06 |
2005-12-22 |
Flavia Pernasetti |
Method and composition for angiogenesis inhibition
|
US7696325B2
(en)
|
1999-03-10 |
2010-04-13 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide inducing apoptosis
|
IL145676A0
(en)
|
1999-04-12 |
2002-06-30 |
Genentech Inc |
Tumor necrosis factor homologs and nucleic acids encoding the same
|
AU3923000A
(en)
*
|
1999-04-16 |
2000-11-02 |
Amgen, Inc. |
Agp-1 fusion protein compositions and methods
|
EP1870464A3
(fr)
*
|
1999-06-02 |
2008-03-12 |
Genentech, Inc. |
Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
|
MXPA01013236A
(es)
*
|
1999-06-28 |
2002-06-21 |
Genentech Inc |
Metodos para hacer ligando apo-2 mediante el uso de iones metalicos divalentes.
|
JP2003510288A
(ja)
*
|
1999-09-30 |
2003-03-18 |
ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア |
Trail:自己免疫性炎症及び細胞周期進行の阻害剤
|
US6444640B1
(en)
*
|
1999-09-30 |
2002-09-03 |
Ludwig Institute For Cancer Research |
Compositions of trail and DNA damaging drugs and uses thereof
|
US6824773B2
(en)
|
1999-12-20 |
2004-11-30 |
Immunex Corporation |
TWEAK receptor
|
WO2001052664A1
(fr)
|
2000-01-24 |
2001-07-26 |
University Of Louisville Research Foundation, Inc. |
Modulation immunitaire avec apoptose induite par recepteur de mort cellulaire
|
US7927602B2
(en)
|
2002-07-23 |
2011-04-19 |
University Of Louisville Research Foundation, Inc. |
Fas ligand-avidin/streptavidin fusion proteins
|
EP1255558B1
(fr)
|
2000-02-16 |
2006-06-14 |
Genentech, Inc. |
Anticorps anti-april et cellules hybridomes
|
US20030103978A1
(en)
*
|
2000-02-23 |
2003-06-05 |
Amgen Inc. |
Selective binding agents of osteoprotegerin binding protein
|
PL357939A1
(en)
|
2000-04-11 |
2004-08-09 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
US6900185B1
(en)
|
2000-04-12 |
2005-05-31 |
University Of Iowa Research Foundation |
Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
|
ATE531789T1
(de)
|
2000-06-30 |
2011-11-15 |
Univ Louisville Res Found |
Zellmembranenveränderung
|
ES2317924T3
(es)
|
2000-07-27 |
2009-05-01 |
Genentech, Inc. |
Administracion secuencial de cpt-11 y polipeptido apo-2l.
|
DE10045591A1
(de)
*
|
2000-09-15 |
2002-04-04 |
Klaus Pfizenmaier |
Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
|
RU2408606C2
(ru)
|
2000-10-20 |
2011-01-10 |
Тугаи Сейяку Кабусики Кайся |
Соединение - агонист тро
|
CA2426710A1
(fr)
*
|
2000-11-08 |
2002-10-10 |
Human Genome Sciences, Inc. |
Anticorps a liaison immunospecifique avec les recepteurs "trail"
|
US20060062786A1
(en)
*
|
2000-11-08 |
2006-03-23 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
US20030228309A1
(en)
*
|
2000-11-08 |
2003-12-11 |
Theodora Salcedo |
Antibodies that immunospecifically bind to TRAIL receptors
|
US20020155109A1
(en)
*
|
2001-04-20 |
2002-10-24 |
Lynch David H. |
Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
|
US7361341B2
(en)
*
|
2001-05-25 |
2008-04-22 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
|
US20050214209A1
(en)
*
|
2001-05-25 |
2005-09-29 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
US20050129616A1
(en)
*
|
2001-05-25 |
2005-06-16 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
CA2446723C
(fr)
|
2001-05-25 |
2014-01-21 |
Human Genome Sciences, Inc. |
Anticorps se liant de maniere immunospecifique a des recepteurs de trail
|
US7348003B2
(en)
|
2001-05-25 |
2008-03-25 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
|
US20090226429A1
(en)
*
|
2001-05-25 |
2009-09-10 |
Human Genome Sciences, Inc. |
Antibodies That Immunospecifically Bind to TRAIL Receptors
|
GB0113920D0
(en)
*
|
2001-06-07 |
2001-08-01 |
Sterix Ltd |
Composition
|
PT2087908T
(pt)
|
2001-06-26 |
2018-07-16 |
Amgen Inc |
Anticorpos contra opgl
|
ATE433996T1
(de)
|
2001-07-03 |
2009-07-15 |
Genentech Inc |
Humane dr4-antikörper und deren anwendungen
|
JP2005502645A
(ja)
*
|
2001-08-08 |
2005-01-27 |
ザ ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
細胞特異的プロモーターからの発現を増幅するための方法
|
EP2348043A1
(fr)
*
|
2001-10-02 |
2011-07-27 |
Genentech, Inc. |
Variantes du ligand APO-2 et leurs utilisations
|
US7741285B2
(en)
|
2001-11-13 |
2010-06-22 |
Genentech, Inc. |
APO-2 ligand/trail formulations
|
AU2007200478A1
(en)
*
|
2001-11-13 |
2007-02-22 |
Genentech, Inc. |
APO2 ligand/trail formulations
|
US7842668B1
(en)
|
2001-11-13 |
2010-11-30 |
Genentech, Inc. |
Apo-2 ligand/trail formulations
|
ES2351786T3
(es)
|
2001-11-13 |
2011-02-10 |
Genentech, Inc. |
Formulaciones con ligando apo2/trail y usos de las mismas.
|
WO2003054216A2
(fr)
*
|
2001-12-20 |
2003-07-03 |
Human Genome Sciences, Inc. |
Anticorps se liant de maniere immunospecifique a des recepteurs trail
|
JP2005521401A
(ja)
|
2002-03-27 |
2005-07-21 |
イミュネックス・コーポレーション |
ポリペプチド産生を増加させる方法
|
AU2003243139B2
(en)
|
2002-04-05 |
2007-06-21 |
Amgen Inc. |
Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
|
US20060141561A1
(en)
|
2002-06-24 |
2006-06-29 |
Kelley Robert F |
Apo-2 ligand/trail variants and uses thereof
|
EP2283869A3
(fr)
|
2002-07-15 |
2012-06-27 |
Board of Regents, The University of Texas System |
Anticorps et peptides de duramycin sélectionnés se liant à des phospholipides et aminophospholipides anioniques et leur utilisation dans le traitement d'infections virales et du cancer
|
AU2003296310A1
(en)
*
|
2002-12-06 |
2004-06-30 |
University Of South Florida |
Histone deacetylase inhibitor enhancement of trail-induced apoptosis
|
JP2004279086A
(ja)
|
2003-03-13 |
2004-10-07 |
Konica Minolta Holdings Inc |
放射線画像変換パネル及び放射線画像変換パネルの製造方法
|
CA2539000A1
(fr)
*
|
2003-09-18 |
2005-03-24 |
Novartis Ag |
Combinaison d'un inhibiteur de l'histone desacetylase avec un ligand des recepteurs de mort
|
CN100549175C
(zh)
*
|
2003-11-03 |
2009-10-14 |
沙东生物药业(天津)有限公司 |
一种具有抑癌作用的重组蛋白及其编码基因与应用
|
US20080206229A1
(en)
|
2003-12-12 |
2008-08-28 |
Koichiro Ono |
Modified Antibodies Recognizing Receptor Trimers or Higher Multimers
|
ME01881B
(fr)
|
2004-01-22 |
2014-12-20 |
Univ Miami |
Formulations topiques de coenzyme q10 et procedes d'utilisation
|
US20080242603A1
(en)
*
|
2004-02-20 |
2008-10-02 |
Yan Wang |
Novel Apo2L and IL-24 Polypeptides, Polynucleotides, and Methods of Their Use
|
CA2558911C
(fr)
|
2004-03-11 |
2016-12-06 |
Genentech, Inc. |
Procede de fabrication de polypeptides
|
AU2005227322A1
(en)
|
2004-03-23 |
2005-10-06 |
Biogen Idec Ma Inc. |
Receptor coupling agents and therapeutic uses thereof
|
CN101035912A
(zh)
|
2004-08-06 |
2007-09-12 |
健泰科生物技术公司 |
使用生物标志的测定法和方法
|
KR101235479B1
(ko)
*
|
2004-08-06 |
2013-02-20 |
제넨테크, 인크. |
바이오마커를 사용한 분석 및 방법
|
NZ553171A
(en)
*
|
2004-09-08 |
2010-03-26 |
Genentech Inc |
Methods of using death receptor ligands and CD20 antibodies
|
NZ553174A
(en)
*
|
2004-09-08 |
2010-03-26 |
Genentech Inc |
Methods of using death receptor ligands Apo2L/Trail and CD20 antibodies
|
EP1645875A1
(fr)
*
|
2004-10-08 |
2006-04-12 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Diagnostic et thérapie de cellules cancéreuses à partir de la résistance à l'apoptose conférée par TRAIL
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
US20060228352A1
(en)
*
|
2005-02-24 |
2006-10-12 |
Schoenberger Stephen P |
TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
|
JP2006265155A
(ja)
*
|
2005-03-23 |
2006-10-05 |
Link Genomics Kk |
癌の免疫療法
|
JP5057967B2
(ja)
|
2005-03-31 |
2012-10-24 |
中外製薬株式会社 |
sc(Fv)2構造異性体
|
JP5085322B2
(ja)
|
2005-06-10 |
2012-11-28 |
中外製薬株式会社 |
sc(Fv)2を含有する医薬組成物
|
KR101367544B1
(ko)
|
2005-06-10 |
2014-02-26 |
추가이 세이야쿠 가부시키가이샤 |
메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
|
ZA200800969B
(en)
|
2005-08-16 |
2009-08-26 |
Genentech Inc |
Apoptosis sensitivity to APO2L/TRAIL by testing for GalNac-T14 expression in cells/tissues
|
AU2006283174A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Cell-Matrix, Inc. |
Combination therapies for inhibiting integrin-extracellular matrix interactions
|
PE20071101A1
(es)
*
|
2005-08-31 |
2007-12-21 |
Amgen Inc |
Polipeptidos y anticuerpos
|
AU2006318539B2
(en)
|
2005-11-23 |
2012-09-13 |
Genentech, Inc. |
Methods and compositions related to B cell assays
|
GB0524316D0
(en)
*
|
2005-11-29 |
2006-01-04 |
Medical Res Council |
Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
|
US20100047783A1
(en)
*
|
2006-06-20 |
2010-02-25 |
El-Diery Wafik S |
Small molecule modulators of p53 family signaling
|
US8008261B2
(en)
*
|
2006-08-04 |
2011-08-30 |
Mayo Foundation For Medical Education And Research |
Methods of reducing trail-induced apoptosis by trail isoforms
|
EP2136831B1
(fr)
|
2007-03-02 |
2012-09-12 |
The Cleveland Clinic Foundation |
Peptides anti-angiogéniques
|
AU2013203061B2
(en)
*
|
2007-07-10 |
2016-07-28 |
Apogenix Ag |
TNF superfamily collectin fusion proteins
|
CA2860950C
(fr)
|
2007-07-10 |
2017-08-01 |
Apogenix Gmbh |
Proteines de fusion collectines de la superfamille des tnf
|
WO2009025743A2
(fr)
*
|
2007-08-17 |
2009-02-26 |
University Of Massachusetts Medical School |
Utilisation de compositions trail en tant qu'agents antiviraux
|
CN101157729B
(zh)
*
|
2007-10-23 |
2011-01-12 |
南京大学 |
一种肿瘤坏死因子相关凋亡配体变体及其应用
|
MX2010005104A
(es)
|
2007-11-09 |
2010-08-04 |
Peregrine Pharmaceuticals Inc |
Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
|
WO2010062904A2
(fr)
|
2008-11-25 |
2010-06-03 |
Biogen Idec Ma Inc. |
Utilisation d'antagonistes dr6 et p75 pour favoriser la survie de cellules du systeme nerveux
|
US8664366B2
(en)
|
2009-01-09 |
2014-03-04 |
Apogenix Gmbh |
Fusion proteins forming trimers
|
US20100316639A1
(en)
|
2009-06-16 |
2010-12-16 |
Genentech, Inc. |
Biomarkers for igf-1r inhibitor therapy
|
ES2356880B8
(es)
|
2009-08-21 |
2012-10-30 |
Universidad De Zaragoza |
Liposomas recubiertos con el dominio extracelular de la proteína apo2l/trail.
|
CA2777162A1
(fr)
*
|
2009-10-09 |
2011-04-14 |
Anaphore, Inc. |
Polypeptides qui se lient a l'il-23r
|
WO2011122916A2
(fr)
*
|
2010-04-01 |
2011-10-06 |
한국생명공학연구원 |
Composition pour l'augmentation de la sensibilité de trail contenant un inhibiteur pour l'inhibition de l'expression ou de l'activité de tip41 qui est un gène cible sensibilisateur de trail
|
PL391627A1
(pl)
|
2010-06-25 |
2012-01-02 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Przeciwnowotworowe białko fuzyjne
|
CN103080300B
(zh)
|
2010-08-05 |
2015-11-25 |
安姆根有限公司 |
增加细胞培养物的产率和活力的二肽
|
EP2646464B1
(fr)
|
2010-12-03 |
2015-06-03 |
Adamed sp. z o.o. |
Protéine de fusion anticancéreuse
|
PL219845B1
(pl)
|
2011-01-05 |
2015-07-31 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Przeciwnowotworowe białko fuzyjne
|
PL394618A1
(pl)
|
2011-04-19 |
2012-10-22 |
Adamed Spólka Z Ograniczona Odpowiedzialnoscia |
Przeciwnowotworowe bialko fuzyjne
|
US9133493B2
(en)
|
2011-04-21 |
2015-09-15 |
Amgen Inc. |
Method for culturing mammalian cells to improve recombinant protein production
|
JP2014513128A
(ja)
|
2011-05-03 |
2014-05-29 |
ジェネンテック, インコーポレイテッド |
血管破壊剤とその使用
|
PL2726600T3
(pl)
|
2011-07-01 |
2017-08-31 |
Amgen Inc. |
Hodowla ssaczych komórek
|
CN102908612A
(zh)
*
|
2011-08-02 |
2013-02-06 |
北京诺赛基因组研究中心有限公司 |
TRAIL截短型变异体活化NF-κB和在炎症反应中的应用
|
AU2012301656A1
(en)
|
2011-09-02 |
2014-01-16 |
Amgen Inc. |
Pharmaceutical product and method of analysing light exposure of a pharmaceutical product
|
CN103534273B
(zh)
*
|
2011-09-16 |
2020-05-12 |
北京沙东生物技术有限公司 |
环化变构trail/apo2l及其编码基因与应用
|
PL397167A1
(pl)
|
2011-11-28 |
2013-06-10 |
Adamed Spólka Z Ograniczona Odpowiedzialnoscia |
Przeciwnowotworowe bialko fuzyjne
|
AR089231A1
(es)
|
2011-12-15 |
2014-08-06 |
Amgen Inc |
Metodo de floculacion
|
PL223487B1
(pl)
|
2011-12-28 |
2016-10-31 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Przeciwnowotworowe białko fuzyjne
|
CA2893883A1
(fr)
*
|
2012-12-11 |
2014-06-19 |
Sapiotec Gmbh |
Delphidinine pour lutter contre des cellules de melanome
|
US20150353542A1
(en)
|
2013-01-14 |
2015-12-10 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
US10023608B1
(en)
|
2013-03-13 |
2018-07-17 |
Amgen Inc. |
Protein purification methods to remove impurities
|
TWI625390B
(zh)
|
2013-03-14 |
2018-06-01 |
安美基公司 |
用於增加重組蛋白質之甘露糖含量之方法
|
SI2970473T1
(sl)
|
2013-03-14 |
2017-10-30 |
Bristol-Myers Squibb Company |
Kombinacija dr5 agonista in anti-pd-1 antagonista in postopek uporabe
|
US20160024144A1
(en)
|
2013-03-14 |
2016-01-28 |
Amgen Inc. |
Removal of leaked affinity purification ligand
|
US9481901B2
(en)
|
2013-05-30 |
2016-11-01 |
Amgen Inc. |
Methods for increasing mannose content of recombinant proteins
|
NZ714347A
(en)
|
2013-06-25 |
2020-01-31 |
Walter & Eliza Hall Inst Medical Res |
Method of treating intracellular infection
|
CN103555729B
(zh)
*
|
2013-10-14 |
2016-08-24 |
成都华创生物技术有限公司 |
一种改造的trail基因序列、表达方法及应用
|
MX2016005572A
(es)
|
2013-10-31 |
2016-12-09 |
Amgen Inc |
Uso de monensina para regular la glicosilacion de proteinas recombinantes.
|
WO2015105609A1
(fr)
|
2014-01-13 |
2015-07-16 |
Amgen Inc. |
Régulation du métabolisme de l'ornithine pour manipuler la teneur en glycoformes à haute teneur en mannose de protéines de recombinaison
|
US10106829B2
(en)
|
2014-01-29 |
2018-10-23 |
Amgen Inc. |
Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
IL282517B
(en)
|
2014-01-29 |
2022-07-01 |
Amgen Inc |
Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
US11299528B2
(en)
|
2014-03-11 |
2022-04-12 |
D&D Pharmatech Inc. |
Long acting TRAIL receptor agonists for treatment of autoimmune diseases
|
SG10202113019XA
(en)
|
2014-06-04 |
2021-12-30 |
Amgen Inc |
Methods for harvesting mammalian cell cultures
|
EP3221465B1
(fr)
|
2014-11-19 |
2019-03-13 |
Amgen Inc. |
Quantification de la fraction glycane dans des glycoprotéines recombinantes
|
WO2016089919A1
(fr)
|
2014-12-01 |
2016-06-09 |
Amgen Inc. |
Procédé de manipulation du taux de contenu de glycane d'une glycoprotéine
|
US11279768B1
(en)
|
2015-04-03 |
2022-03-22 |
Precision Biologics, Inc. |
Anti-cancer antibodies, combination therapies, and uses thereof
|
CA3008392C
(fr)
|
2015-12-17 |
2021-11-09 |
The Johns Hopkins University |
Amelioration de la sclerose systemique a l'aide d'agonistes de recepteurs de mort cellulaire
|
CA3007419A1
(fr)
|
2015-12-30 |
2017-07-06 |
Genentech, Inc. |
Formulations presentant une moindre degradation des polysorbates
|
CN116064677A
(zh)
*
|
2016-02-05 |
2023-05-05 |
斯比根公司 |
表达trail和cd的间充质干细胞及其用途
|
JP7281795B2
(ja)
|
2016-04-07 |
2023-05-26 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法
|
KR101739703B1
(ko)
*
|
2016-09-13 |
2017-05-24 |
(주) 어드밴스드 엔티 |
Trail 기반 뇌염 감별진단 방법 및 장치
|
US11519007B2
(en)
|
2019-02-22 |
2022-12-06 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Tumor-navigating, self-eradicating, trail-armed salmonella for precision cancer therapy
|
WO2023129974A1
(fr)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Génération de lignées de cellules avec site d'intégration
|